ROMIAE (Rule-Out Acute Myocardial Infarction Using Artificial Intelligence Electrocardiogram Analysis) Trial
ROMIAE
A Prospective, Multicenter, Observational Diagnostic Study to Externally Validate an Artificial Intelligence 12-lead Electrocardiogram Analysis Algorithm to Detect Patients With Acute Myocardial Infarction Who Visit Emergency Medical Center
1 other identifier
observational
8,814
1 country
1
Brief Summary
This study is a prospective multicenter observational study for external validation and model advancement of a deep learning based 12-lead electrocardiogram analysis algorithm targeting adult patients presenting to the emergency department with chest pain and acute myocardial infarction equivalent symptoms. About 9,000 adult patients will be enrolled at 20 emergency medical centers in Korea. Artificial intelligence algorithms are manufactured by Medical AI Co., Ltd. It is an advanced version based on the model developed and published in 2020. It had the diagnostic performance of area under the receiver operating curve 0.901 and 0.951 for acute myocardial infarction and ST-segment elevation myocardial infarction, respectively. The primary endpoint is a diagnosis of acute myocardial infarction on the day of the emergency center visit, and the secondary endpoint is a 30-day major adverse cardiac event. From March 2022, patient registration will begin at centers that have been approved by the Institutional Review Board. This is the first prospective multicenter emergency department validation study for a 12-lead electrocardiogram artificial intelligence algorithm to diagnose acute myocardial infarction. This study will give insight into the direction of future development by verifying whether the deep learning algorithm works well for patients visiting the real-world adult emergency medical center.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 16, 2022
CompletedFirst Submitted
Initial submission to the registry
June 13, 2022
CompletedFirst Posted
Study publicly available on registry
June 28, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2023
CompletedJune 28, 2022
April 1, 2022
12 months
June 13, 2022
June 22, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Diagnosis of acute myocardial infarction (Type 1, 2)
Accuracy metrics include area under the receiver operating characteristics curve, sensitivity, specificity, positive predictive value, and negative predictive value, along with a 95% confidence interval.
Index admission
Secondary Outcomes (1)
Major adverse cardiovascular event (MACE)
30-day after index admission
Other Outcomes (4)
AI ECG analysis versus clinical risk score (HEART score)
Index admission, 30-day after index admission
AI ECG analysis versus clinical risk score (GRACE 2.0 score)
Index admission, 30-day after index admission
AI ECG analysis versus cardiac biomarker
Index admission
- +1 more other outcomes
Study Arms (1)
Group 1
Patients with chest pain or who are clinically suspected as acute myocardial infarction with equivalent symptoms.
Eligibility Criteria
A total of 20 emergency departments in the Republic of Korea will participate in this study. These centers receive about 800,000 patients annually, and all of these hospitals are capable of their own emergency cardiovascular angiography and percutaneous coronary intervention.
You may qualify if:
- Adults over 18 years of age with suspected chest pain and acute myocardial infarction
- The onset or worsening of the symptom occurs within 24 hours
You may not qualify if:
- Out-of-hospital cardiac arrest (OHCA): patients with sustained (\>20 minutes) return-of-spontaneous-circulation are not excluded
- Patients in whom acute myocardial infarction can be clearly excluded, such as pneumothorax and traumatic chest pain
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- CHA Universitylead
- Medical AI Co., Ltdcollaborator
Study Sites (1)
CHA Bundang Medical Center
Seongnam, South Korea
Related Publications (1)
Shin TG, Lee Y, Kim K, Lee MS, Kwon JM; ROMIAE study group. ROMIAE (Rule-Out Acute Myocardial Infarction Using Artificial Intelligence Electrocardiogram Analysis) trial study protocol: a prospective multicenter observational study for validation of a deep learning-based 12-lead electrocardiogram analysis model for detecting acute myocardial infarction in patients visiting the emergency department. Clin Exp Emerg Med. 2023 Dec;10(4):438-445. doi: 10.15441/ceem.22.360. Epub 2023 Nov 28.
PMID: 38012820DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
KS Kim, MD, PhD
CHA University School of Medicine
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 13, 2022
First Posted
June 28, 2022
Study Start
March 16, 2022
Primary Completion
March 1, 2023
Study Completion
May 1, 2023
Last Updated
June 28, 2022
Record last verified: 2022-04
Data Sharing
- IPD Sharing
- Will not share